K101856

510(k) Summary

OCT - 5 2010

Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

Submitter name, address, contact

Roche Diagnostics
9115 Hague Road, P.O. Box 50416
Indianapolis, IN 46250-0416
317-521-3501

Contact Person: Jason Fisher
Phone: 317-521-3501
Fax: 317-521-2324
Email: jason.fisher@roche.com

Secondary Contact: Stephanie Greeman
Phone: 317-521-2458
Fax: 317-521-2324
Email: stephanie.greeman@roche.com

Date Prepared: June 30, 2010

Device Name

Proprietary name: Elecsys CEA CalCheck 5
Common name: CEA CalCheck 5
Classification name: Single (specified) analyte controls (assayed and unassayed)

Predicate device

The Elecsys CEA CalCheck 5 is substantially equivalent to other products in commercial distribution intended for similar use. We claim equivalency to the currently marketed Elecsys C-Peptide CalCheck 5 (K100810) and the Elecsys CEA CalCheck (K970452).

Device Description

The Elecsys CEA CalCheck 5 is a lyophilized product consisting of human CEA in human serum matrix. During manufacture, the analyte is spiked into the matrix at the desired concentration levels.

Intended use

The Elecsys CEA CalCheck 5 is an assayed control for use in calibration verification and for use in the verification of the assay range established by the Elecsys CEA CalCheck quantitative assay reagent on the indicated Elecsys and cobas e immunoassay analyzers. For in vitro diagnostic use only.

Continued on next page

Comparison Table

The table below compares Elecsys CEA CalCheck 5 with the predicate devices, Elecsys C-Peptide CalCheck 5 (K100810) and the CEA CalCheck (K970452).

Please note that the use of two predicates has been utilized for this submission based on previous FDA feedback to several of the most recently FDA-cleared CalCheck 5 products. The first predicate shows that the CEA CalCheck 5 is substantially equivalent to another CalCheck 5 product. The Elecsys CEA CalCheck 5 is also substantially equivalent to the second predicate, CEA CalCheck, with several key similarities, especially the analyte. The shaded fields indicate similar characteristics between the candidate device and a predicate device.

Characteristic	**Elecsys C-Peptide CalCheck 5 (K100810)**	**Elecsys CEA CalCheck 5 (Candidate Device)**	**Elecsys CEA CalCheck (K970452)**
Intended Use	The Elecsys C-Peptide CalCheck 5 is an assayed control for use in calibration verification and for use in the verification of the serum and plasma assay range established by the Elecsys C-Peptide reagent on the indicated Elecsys and **cobas e** immunoassay analyzers.	The Elecsys CEA Calcheck 5 is an assayed control for use in calibration verification and for use in the verification of the assay range established by the Elecsys CEA reagent on the indicated Elecsys and **cobas e** immunoassay analyzers.	For use in the verification of the calibration established by the Elecsys CEA reagent on the indicated Elecsys and **cobas e** immunoassay analyzers.
Analyte	C-Peptide	CEA	CEA
Levels	Five	Five	Three
Format	Lyophilized	Same	Same
Handling	Reconstitute Check 1, Check 2, Check 3, Check 4, and Check 5 with exactly 1.0 mL distilled or deionized water. Allow to stand closed for 15 minutes, then mix gently by inversion.	Reconstitute Check 1, Check 2, Check 3, Check 4, and Check 5 with exactly 1.0 mL distilled or deionized water. Allow to stand closed for 15 minutes, then mix gently by inversion.	Reconstitute Check 1, Check 2, and Check 3 with exactly 1.0 mL distilled or deionized water. Allow to stand closed for 15 minutes, then mix gently by inversion.
Stability	Unopened: • Store at 2-8°C until expiration date Reconstituted: • 20-25°C: 4 hours	Unopened: • Store at 2-8°C until expiration date Reconstituted: • 20-25°C: 4 hours	Unopened: • Store at 2-8°C until expiration date Reconstituted: • 15-25°C: 4 hours
Matrix	Equine serum matrix	Human serum matrix	Human serum matrix

Performance Characteristics

The Elecsys CEA CalCheck 5 was evaluated for value assignment and stability.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food & Drug Administration
10903 New Hampshire Avenue
Building 66
Silver Spring, MD 20993

Roche Diagnostics
Roche Diagnostics Operations, Inc.
c/o Mr. Jason D. Fisher
Regulatory Affairs Principal
9115 Hague Road
Indianapolis, IN, 46250-0457

OCT 05 2010

Re: k101856
Trade/Device Name: Elecsys CEA CalCheck 5
Regulation Number: 21 CFR§862.1660
Regulation Name: Quality Control Material, Assayed and Unassayed
Regulatory Class: Class I (Reserved)
Product Code: JJX
Dated: September 7, 2010
Received: September 8, 2010

Dear Mr. Fisher:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

for Maria M. Chan, Ph.D.
Director
Division of Immunology and Hematology Devices
Office of *In Vitro* Diagnostic Device Evaluation and Safety
Center for Devices and Radiological Health

Enclosure

Indication for Use

K101856
OCT - 5 2010

510(k) Number (if known): K101856

Device Name: Elecsys CEA CalCheck 5

Indication For Use:

The Elecsys CEA CalCheck 5 is an assayed control for use in calibration verification and for use in the verification of the assay range established by the Elecsys CEA CalCheck quantitative assay reagent on the indicated Elecsys and cobas e immunoassay analyzers. For in vitro diagnostic use only.

Prescription Use __X____ (21 CFR Part 801 Subpart D) And/Or Over the Counter Use ____. (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

Division Sign-Off
Office of In Vitro Diagnostic Device
Evaluation and Safety

510(k) k101856